查找地点
有关时间、上门服务和预约查找地点
有关时间、上门服务和预约This test may exhibit interference when sample is collected from a person who is consuming a supplement with a high dose of biotin (also termed as vitamin B7 or B8, vitamin H, or coenzyme R). It is recommended to ask all patients who may be indicated for this test about biotin supplementation. Patients should be cautioned to stop biotin consumption at least 72 hours prior to the collection of a sample.
1 - 2 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Serum or plasma
1 mL
0.4 mL (Note: This volume does not allow for repeat testing.)
Red-top tube, gel-barrier tube or lavender-top (EDTA) tube
If tube other than a gel-barrier tube is used, transfer separated serum or plasma to a plastic transport tube. Do not freeze gel-barrier tube (pour off serum first).
Room temperature
Temperature | Period |
---|---|
Room temperature | 14 days |
Refrigerated | 14 days |
Frozen | 14 days |
Freeze/thaw cycles | Stable x3 |
Non-EDTA plasma specimen; PST gel-barrier tube; grossly hemolyzed specimens
This assay is used to detect total antibodies (IgG and IgM) against Hepatitis A virus (HAV) and may be helpful when assessing HAV immunity. The detection of total antibodies cannot differentiate between vaccination, previously resolved infection, or active infection. If active hepatitis A infection is suspected, HAV IgM testing should be performed. Hepatitis A is a vaccine-preventable disease of the liver caused by the Hepatitis A virus (HAV). HAV is transmitted via the fecal-oral route, usually from direct person-to-person contact or consumption of contaminated food or water. Hepatitis A is an acute, self-limited disease that does not result in chronic infection. HAV IgG antibodies produced in response to vaccination and/or HAV infection persist for life and protect against reinfection.
This assay has not been FDA cleared or approved for the screening of blood or plasma donors. Assay performance characteristics have not been established for immunocompromised or immunosuppressed individuals. This assay does not differentiate IgG and IgM.
Immunochemiluminometric assay (ICMA)
Negative
See table.
HAV antibody testing interpretation chartHAV Total Antibody | HAV IgM | Comments |
---|---|---|
Negative | Not done | No evidence of vaccination or previous infection; Susceptible to Hepatitis A infection |
Positive | Not done | Consistent with recent or remote Hepatitis A infection or antibody response to HAV vaccination |
Positive | Negative | Consistent with resolved Hepatitis A infection or antibody response to HAV vaccination |
Positive | Positive | Consistent with active Hepatitis A infection |
Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
---|---|---|---|---|---|---|
006726 | Hep A Ab, Total | 13951-9 | 006726 | Hep A Ab, Total | 13951-9 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf